Pay in 4 interest-free payments of $7.11 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
It is only accessible within approved clinical trial settings, and patients should be cautious of unregulated sources offering it outside of trials
Description How It Works BPC-157 is studied for its ability to trigger essential repair pathways, including: Stimulating Angiogenesis: Inducing the formation of new blood vessels to improve nutrient delivery to damaged areas
Subcutaneous placement sits shallow and matches frequent schedules
As of September 2023 it is on the FDA Category 2 list of bulk drug substances that may not be compounded, and a PCAC review is scheduled for July 2026 under the name Emideltide
Collagen fiber alignment, a key determinant of tendon tensile strength, appears to improve in BPC-157-treated tissue in animal models compared to untreated controls
Zhang, Q., Yan, L., Lu, J., & Zhou, X
